Four virus serotypes…One Dengue vaccine?
Could targeting CCR5 cure HIV?
The rise in Zika virus research — an update
Be the first to know when we launch new products and resources to help you achieve more in the lab.
The dengue virus (DENV), first isolated in 1943, is assigned to the family Flaviviridae, genus Flavivirus. It has four serotypes (DENV-1, DENV-2, DENV-3, and DENV-4) and transmission to humans occurs via the Aedes mosquito, mainly Aedes aegypti. Its global reach has mirrored the spread of Aedes aegypti in tropical and subtropical areas (Messina et al. 2014). It is suggested that 390 million dengue infections occur per year, of which 96 million develop symptoms (Bhatt et al. 2013).
After being exposed to the virus (of any DENV serotype) through a mosquito bite, an incubation period of 4-7 days follows. Then symptoms tend to be noticed for the next 5 days, but not all infected individuals show signs of illness (Bhatt et al. 2013). This is called dengue fever (DF) and is similar to mild flu-like syndrome. Some hemorrhagic manifestations, such as petechiae, may occur. The next form is dengue hemorrhagic fever (DHF) which adds thrombocytopenia, coagulopathy, and vascular fragility and permeability. The most severe form, dengue shock syndrome (DSS), is characterized by a rapid, weak pulse, and may progress to hypovolemic shock and death (Carlos et al. 2005).
DENV has an outer icosahedral shell and a lipid bilayer that surrounds the nucleocapsid which contains the 11,000 kb positive- and single-stranded RNA (ssRNA) genome with a single open reading frame (Kuhn et al. 2002) that codes for:
The E protein forms the outer layer (90 E fusion protein pairs) and also binds the cellular receptors and initiates fusion with the host cell (Chambers et al. 1990). The next lower layer is made up of the M protein. In the immature DENV, the prM protein forms a trimer with the E protein pairs, resulting in the appearance of spikes on the virion surface (Zhang et al. 2003). At the core the C protein forms the container for the viral RNA.
The NS proteins have roles in viral replication and host immune system evasion. Of these, NS3 and NS5 are better defined than the other NS proteins. NS3 is a viral protease and helicase, which cleaves the single viral polypeptide into the seven proteins and unwinds the RNA duplex during replication, respectively. NS2b serves as a cofactor for the protease activity (Falgout et al. 1991) while NS4b interacts with the helicase domain (Umareddy et al. 2006). NS5 is the RNA-dependent RNA polymerase that also functions as a methyltransferase, which caps the 5′-RNA of new viral genomes (Issur et al. 2009). The functions of the NS1 and the transmembrane proteins NS2a, NS2b, NS4a, and NS4b are less well defined. NS1 is essential for viral replication (Lindenbach and Rice 1999) and together with NS4a and NS4b, aids in vesicle formation for the viral replication complex (RC) (Watterson et al. 2016). NS2a is required for viral RNA synthesis and virion assembly (Xie et al. 2015).
Dengue virus life cycle.
The Aedes mosquito is the vector that spreads DENV to humans. The precise binding receptors have not been fully defined yet, but candidate receptors are: heparan sulfate, glycosphingolipid nLc4Cer, DC-SIGN, mannose, CD14, and HSP70/90 (Cruz-Oliveira et al. 2015). Similarly, several cell types have been found to be permissive for DENV infection; they are: dendritic cells (DCs), endothelial cells, fibroblasts, keratinocytes, macrophage, mast cells, and monocytes (Garcia et al. 2017). The replication steps have been defined as:
(Mackenzie 2005, Mukhopadhyay et al. 2005, Welsch et al. 2009)
On cell entry, the DENV RNA will be detected in innate immune cells by the pattern recognition receptors (PRR), retinoic acid-inducible gene I (RIG-I), melanoma differentiation-associated protein 5 (MDA5), Toll-like receptor 3 (TLR3), and TLR7 (Nasirudeen et al. 2011, Wang et al. 2006). Activation of these receptors will trigger type 1 interferon (IFN) responses. The mannose-binding lectin (MBL) recognizes mannose glycans on DENV and activates the classical complement cascade resulting in the formation of the membrane attack complex (MAC) to lyse virions, recruit phagocytes, and drive inflammation (Fujita et al. 2004).
Our recombinant DENV NS1 proteins are available in their native folded state complete with post-translational modifications. This allows them to deliver optimal antigenicity and makes them suitable for use in vaccine research and serology-based assays. The recombinant DENV NS1 proteins are available in all four serotypes.
Bio-Rad also offers a DENV type 2 inactivated pathogen along with two antibodies to the virus. 2645-5057, clone 3H5.1, in purified format, works in immunofluorescence and recognizes the dengue virus type 2. MCA2277, clone dengue 1-11 (3), also available in purified format, binds all four serotypes of DENV and can be used in ELISA, immunofluorescence, western blotting, and in immunohistology on paraffin embedded tissue sections. Additionally, an antibody, clone 6b6c-1, to the Saint Louis Encephalitis virus strain (MSI-7) envelope glycoprotein is available. This clone also reacts with other members of Flaviviridae including; Dengue 1 (Hawaii), Dengue 2 (New Guinea C), Dengue 3 (H87), and Dengue 4 (H241).
|PIP047B||DENGUE Virus Type 1 NS1 Antigen||Rec. Protein||Viral||E|
|PIP048B||DENGUE Virus Type 2 NS1 Antigen||Rec. Protein||Viral||E|
|PIP049A||DENGUE Virus Type 3 NS1 Antigen||Rec. Protein||Viral||E|
|PIP050B||DENGUE Virus Type 4 NS1 Antigen||Rec. Protein||Viral||E|
|PIP006||DENGUE Virus Type 2 antibody||Inactivated Pathogen||Viral||E|
|2645-5057||DENGUE Virus antibody: Purified||Viral||Mouse||IgG1||3H5.1||IF|
|MCA2277||DENGUE Virus antibody: Purified||Viral||Mouse||IgG2a||Dengue 1-11(3)||E, P*, WB|
|OBT1676||ST. Louis Encephalitis Virus antibody: Purified||Viral||Mouse||IgG2a||6b6c-1||E, IF|